Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pediatric clinical research.

Daniel J Lovell1, Natasha M Ruth

  • 1Cincinnati Children's Hospital, Cincinnati, Ohio 45229, USA. Daniel.lovell@cchmc.org

Current Opinion in Rheumatology
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.

Annals of the rheumatic diseases·2026
Same author

Can Medical Students Learn the Pediatric Musculoskeletal Examination Independently?

Southern medical journal·2026
Same author

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis.

Arthritis care & research·2025
Same author

Post-Streptococcal Myositis: Etiology of Myalgia and Severe Inflammation in a Child.

Pediatrics·2025
Same author

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

This review covers advancements in diagnosing and treating childhood-onset systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis, focusing on improving quality of life for affected children.

Area of Science:

  • Pediatric Rheumatology
  • Autoimmune Diseases in Children
  • Inflammatory Conditions

Background:

  • Childhood-onset systemic lupus erythematosus (cSLE), juvenile idiopathic arthritis (JIA), and juvenile dermatomyositis (JDM) are significant pediatric rheumatic diseases.
  • These conditions impact children's health-related quality of life (HRQoL).
  • Understanding disease mechanisms and treatment responses is crucial for effective management.

Purpose of the Study:

  • To review recent progress in the diagnosis and treatment of cSLE, JIA, and JDM.
  • To highlight strategies aimed at enhancing HRQoL in pediatric rheumatic diseases.
  • To synthesize key findings on disease activity markers and therapeutic interventions.

Main Methods:

  • Literature review of recent studies on cSLE, JIA, and JDM.

Related Experiment Videos

  • Analysis of diagnostic markers and imaging techniques.
  • Evaluation of treatment outcomes, including medication efficacy and novel therapies.

    • Main Results:

    • Atherosclerosis risk factors in cSLE include insulin, lipoproteins, and oxidized markers.
    • Myeloid-related proteins (S100A8/A9) and S100A12 indicate disease activity in JIA.
    • MRI and CT reveal cartilage changes and bone geometry issues in JIA.
    • Subcutaneous methotrexate is effective for methotrexate-resistant JIA.
    • Synovial inflammation influences relapse in JIA.
    • Quantitative MRI and MHC Class I expression are noted in early JDM.
    • Intravenous cyclophosphamide and tacrolimus ointment show promise for refractory JDM.

    Conclusions:

    • Significant advancements have been achieved in the diagnosis and treatment of cSLE, JIA, and JDM.
    • Ongoing research continues to refine management strategies for these pediatric autoimmune conditions.
    • Improving HRQoL remains a key objective in the care of children with these diseases.